SQI Diagnostics

SQI Diagnostics is a medical systems automation company focused on evolving laboratory-based biomarker testing. Using automation and proprietary miniaturization technologies, SQI Diagnostics significantly improves the economies of scale for laboratories performing multi-analyte biomarker testing, allowing them to deliver patient results faster, using less labor, and fewer resources. SQI Diagnostics' initial products target the autoimmune disease market, with initial products for rheumatoid arthritis and antiphospholipid syndrome scheduled for launch in 2008. SQI Diagnostics is based in Toronto, Canada.